Albert Vanderlaan is a partner in Orrick’s Technology Companies Group. He works with public and private companies, venture capital firms and investment banks focused on the life sciences and high-growth technology sectors.

Albert is involved in a broad range of corporate legal engagements for high growth technology companies, including venture financings, public offerings, private and public company securities law compliance matters, public company disclosure obligations,  mergers and acquisitions and COVID-19 related matters (including public company disclosure matters and Paycheck Protection Act eligibility and compliance matters) . He also regularly advises private and public companies and their board of directors on corporate governance issues. Albert's clients include private and public companies in the life sciences (including, among others, immuno-oncology, gene therapy, restorative cell therapy and medical device companies), real estate, finance and Internet related industries. He also represents underwriters in initial public offerings, follow-on offerings and PIPE offerings and venture capital firms in a variety of investment transactions.
  • Prior to joining Orrick, Albert was an attorney with Gunderson Dettmer and Cooley.
  • Albert's engagements include:

    • Histogenics Corporation in its reverse merger with Ocugen, Inc.
    • A syndicate of institutional investors in the pre-IPO convertible note financing of Phathom Pharmaceuticals, Inc.
    • ARMO BioSciences, Inc. in its acquisition by Eli Lilly for $1.6 billion
    • Fisker Inc. in its pending sale to Spartan Energy Acquisition Corp., a SPAC sponsored by an affiliate of Apollo Global Management, Inc. ($2.9 billion)
    • Vanda Pharmaceuticals Inc. in its $101 million follow-on public offering
    • Histogenics Corporation in its $17 million follow-on public offering
    • Histogenics Corporation in its $6.325 million registered direct offering
    • Synchronoss Technologies, Inc. in its sale of Intralinks Holdings, Inc. for $977 million
    • Partner Therapeutics, Inc. in its acquisition of assets related to Leukine from sanofi-aventis U.S. LLC
    • Synchronoss Technologies, Inc. in its acquisition of Intralinks Holdings, Inc. for $821 million
    • REGENXBIO Inc. in its $250 million IPO
    • Synchronoss Technologies, Inc. in its $230 million offering of 0.75% senior convertible notes
    • Vitae Pharmaceuticals, Inc. in its acquisition by Allergan for $639 million

    Please note: Albert's experience includes that prior to joining Orrick.

Insights

News